Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onglyza

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

AstraZeneca wins stay on Crestor generics in US

Appeals court upholds earlier ruling to validate patent until 2016

- PMLiVE

AstraZeneca’s fostamatinib fails to match Humira in RA

Inferiority to Abbott’s drug dents commercial prospects

- PMLiVE

AstraZeneca antitrust fine upheld by European Court of Justice

Lessons for pharma as landmark ruling stands

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

FDA approves Exelixis’ Cometriq for rare thyroid cancer

Genomics-based discovery company also submits the drug to EU regulators

- PMLiVE

Ranbaxy recalls generic Lipitor in US

Several batches withdrawn after some products found to contain small particles of glass

- PMLiVE

Depth perception: diabetes in India

Using digital, pharma can engage with diabetes patients in India and build a 3D image of their needs

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

NIHR launches online diabetes research showcase

Aims to raise public aware of diabetes and the importance of research

- PMLiVE

Sanofi and T1D Exchange collaborate to understand needs of children living with diabetes

Aims to deliver recommendations for better disease management and patient outcomes

- PMLiVE

EU approval for AZ/BMS’ first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links